AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01517620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Glucosides Paeony Capsules
Description: Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
Study NCT04208997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug
Description: Continuation of amiodarone or sotalol.
Study NCT00183820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel, gemcitabine, and oxaliplatin
Description: 1. Paclitaxel 170 mg/m2 IV d 1 14 days~2. Gemcitabine 800 mg/m2 IV d 1 14 days~3. Oxaliplatin 100 mg/m2 IV d 1 14 days
Study NCT04125888 — intervention group
Intervention type: DRUG
Intervention: Allergy immunotherapy (AIT)
Description: Immunotherapy for different types of allergies
Study NCT05235048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Atraumatic tooth extraction without flap elevation
Study NCT05235048 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tooth extraction
Description: Atraumatic tooth extraction without flap elevation
Study NCT02610556 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Intensity-modulated radiotherapy
Study NCT04653909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The abdominal and back strengthening exercises on the mat, the open-closed perturbation training in sitting and standing positions for trunk control. Functional exercises were performed in the same positions for simulating daily living activities. The stretching and strengthening exercises were applied to her scoliosis and also given trunk orthoses.
Study NCT03192982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-V impulse 6000 Series
Description: foot pad and pump
Study NCT03192982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (compression)
Description: Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
Study NCT02692339 — intervention group
Intervention type: DRUG
Intervention: Lenalidomide
Description: Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
Study NCT02692339 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Study NCT03448718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to \< 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction cisplatin
Description: 15 mg/m\^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction 5-fluorouracil
Description: 400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
Study NCT00777491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction gemcitabine
Description: 27 mg/m\^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
Study NCT05235048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with connective tissue graft
Description: Atraumatic tooth extraction without flap elevation and seal of the alveolar socket with connective tissue graft (microsurgery)
Study NCT05235048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with BRG and connective tissue graft and
Description: Atraumatic tooth extraction without flap elevation, position of a bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
Study NCT05235048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction and socket seal with membrane placement, BRG and connective tissue graft
Description: Atraumatic tooth extraction without flap elevation, position of a collagen membrane and bone replacement graft into the socket and seal of the alveolar socket with connective tissue graft (microsurgery)
Study NCT01172522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine 1%
Study NCT01172522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04537429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: up to four iv infusions of eptinezumab
Study NCT03219541 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interventional Automated mobile phone text
Description: Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
Study NCT03219541 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Automated mobile phone text
Description: Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
Study NCT02284516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast Ophthalmic Solution 5%, BID for 84 days
Study NCT02284516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match active treatment, BID for 84 days
Study NCT02198872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise, Aerobic (Water based)
Description: Patients of this group will be submitted to an aerobic water based physical training
Study NCT02198872 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land Group
Description: Patients of this group perform physical training on bicycle.
Study NCT02863276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy
Study NCT01422018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab)
Description: Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
Study NCT01899664 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve Transfer Surgery
Description: Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
Study NCT01979965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine (Active drug)
Description: Ranolazine therapy for three months
Study NCT01979965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo therapy for three months
Study NCT02048969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
Study NCT02048969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
Study NCT03212690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local standard of care
Description: Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
Study NCT03212690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Description: Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
Study NCT03282370 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JEVAX
Description: JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
Study NCT03282370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
Study NCT01595633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switching from adefovir (10mg/day) to tenofovir (300mg/day)
Description: active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
Study NCT01595633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching from adefovir (10mg/day) to tenofovir (300mg/day)
Description: active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
Study NCT00936611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study NCT03724786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Six-hour urine protein collection
Description: This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
Study NCT03748108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
Study NCT03748108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
Study NCT03949439 — intervention group
Intervention type: PROCEDURE
Intervention: Elective Cardiac Surgery
Description: Surgical interventions (coronary artery bypass \[CAB\], valve replacement or valve repair).
Study NCT01015599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOP'N After-school Program
Description: Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
Study NCT01781754 — intervention group
Intervention type: PROCEDURE
Intervention: Blood withdrawal
Description: This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
Study NCT00147212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET 743
Description: ET-743 administered IV by 24-hr infusion every 3 weeks
Study NCT01880619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Patients in this arm will receive Tamsulosin 0.4 mg daily
Study NCT01880619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Patients in the arm will receive Solifenacin
Study NCT01880619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients in this are will receive placebo
Study NCT03014557 — intervention group
Intervention type: DEVICE
Intervention: left atrial appendage closure device implantation
Description: to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
Study NCT01423578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hatha Yoga (HY)
Description: 3 Sessions of yoga instruction
Study NCT01423578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Exercise (CE)
Description: 3 sessions of cardiovascular exercise
Study NCT01423578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: 4 smoking cessation counseling visits.
Study NCT01423578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 4 smoking cessation counseling visits.
Study NCT01423578 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking Cessation Counseling
Description: 4 smoking cessation counseling visits.
Study NCT01293773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Element stent
Description: paclitaxel-eluting stent
Study NCT01293773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Integrity Resolute stent
Description: ABT 578-eluting stent
Study NCT01293773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Prime stent
Description: Everolimus-eluting stent
Study NCT02295410 — intervention group
Intervention type: BEHAVIORAL
Intervention: CPT
Study NCT00519454 — intervention group
Intervention type: OTHER
Intervention: Peripheral lab draws
Description: 100ml blood for analysis, taken no more than 4 times in one year.
Study NCT00787761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains > 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration.
Study NCT00787761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses.
Study NCT00787761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume).
Study NCT00787761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes.
Study NCT00787761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push.
Study NCT00787761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F).
Study NCT00787761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic HSCT
Description: As demonstrated by groups in Houston, Jerusalem \& Seattle, RICT has been used to treat hematologic \& solid malignancies with related \& unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute \& chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
Study NCT02162316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motilitone®
Study NCT02162316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-Cilin®, Clari® and Pantoline®
Study NCT02702453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: website
Description: The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
Study NCT03439917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine tartrate
Description: 2g L-Carnitine tartrate as a powder consumed twice a day
Study NCT03439917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacement Drink
Description: 325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
Study NCT03439917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal Replacement Drink
Description: 325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
Study NCT03439917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
Study NCT04314934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Oral capsules
Study NCT02489760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
Study NCT02489760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: The control arm will continue etanercept 25 mg subcutaneously twice a week
Study NCT04214171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gait and muscle strength will be assessed
Description: The extensor moment of the hip during gait and evaluation of the muscular strength of the hip will be evaluated
Study NCT00777491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction BID radiation therapy
Description: Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
Study NCT04511104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance and aerobic exercise in addition to standard of care rehabilitation